Lupus nephritis (LN) is a serious complication of lupus that causes inflammation in the kidneys. If not properly managed, it can lead to permanent kidney damage, dialysis, or even the need for a kidney transplant.
For Black patients, research shows that lupus is more common, more severe, and diagnosed at younger ages compared to other groups. Additionally, Black patients are at greater risk for worse outcomes when lupus attacks the kidneys.
IRIS is a clinical trial evaluating an investigational drug in patients living with lupus nephritis. You may be eligible to participate if you are at least 18 years of age, have been diagnosed with lupus nephritis, and are taking medication to treat it.
Clinical trial participation offers a pathway for those eligible to access a potential new treatment while receiving regular check-ups and assistance in managing their condition. Click here to learn more about a new clinical trial for people with lupus nephritis. Remember that taking part in a clinical trial is always voluntary, and you can opt out at any time.
Why Representation Matters in Research
When it comes to lupus nephritis, representation in clinical trials has been limited. Historically, Black patients have been underrepresented in research despite being disproportionately affected by the disease. This lack of representation creates a significant health gap.
By participating in clinical trials like IRIS, Black patients help researchers better understand how the study medications may affect those who take them. Every participant adds valuable information. Your voice, your experience, and your journey truly matter in shaping the future of lupus care.
Understanding the IRIS Trial
The IRIS clinical trial is studying an investigational treatment for lupus nephritis. The goal is to determine how this treatment affects individuals living with lupus nephritis.
If you qualify and choose to join the study, you’ll be cared for by a dedicated medical team throughout the entire study. Your health and safety will always be our top priority. The doctors and staff will explain the process, answer your questions, and guide you at every step.
Taking part in a clinical trial is always voluntary. If you decide to join IRIS, you’ll not only have the potential to benefit personally but also contribute collectively to the advancement of lupus care.
Trust the Process
It’s no secret that many in the Black community carry deep concerns about clinical research. Today, clinical trials are governed by strict safety rules, and protecting participants is the top priority.
Additionally, the IRIS study team understands that lupus nephritis does not affect everyone equally. By working with patients from different backgrounds, they are committed to making sure the research reflects the real-world experiences of Black communities.
When you participate, you are supported and cared for by a dedicated team throughout the process.
Consider Clinical Trials
Choosing to take part in research is a powerful step. For you, it may mean access to new treatments and closer monitoring of your condition. For the community, it means helping ensure that future lupus nephritis therapies are designed with Black patients in mind.
If you or someone you love is living with lupus nephritis, now is the time to learn more about IRIS. To learn more about the IRIS study and see if you may qualify, click here to take the screener questionnaire.
Content sponsored by AstraZeneca
References:
